16/05/2018 19:19:32

CORRECTING AND REPLACING: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

ORLANDO, Fla., May 16, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today by Hemispherx Biopharma, Inc. (NYSE American:HEB) with the same headline, the net loss from operations was incorrect in the fourth paragraph. It should say $0.07 per share, not $0.70 per share. The corrected release follows.

Hemispherx Biopharma, Inc. (NYSE American:HEB), an advanced specialty pharmaceutical company engaged in the treatment of serious and debilitating disorders through the development of its immunology products Ampligen® and Alferon®, today announced its financial results for the first quarter ended March 31, 2018.

“We made significant progress in the quarter that just ended, including significant improvements to our balance sheet, the production of the equivalent of more than 8,500 vials of Ampligen at our contract fill and finish manufacturer, the expansion of our Ampligen supply agreements for early access programs in Canada and Europe under the management of myTomorrows, and the continuation of our plans to start advanced clinical trials of Ampligen as a single agent and a combination immuno-oncology therapy,” said Thomas K. Equels, Hemispherx’s chief executive officer.

“During the quarter we added to our cash by booking Ampligen sales, the sale/leaseback of our manufacturing facility, the sale of non-strategic real estate, and the exercise of warrants and the sale of common stock,” he continued. “We believe that this will enable us to meet the current and anticipated needs of our commercial channels and clinical study programs, as we work with the FDA to identify a path toward approval for Ampligen for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” 

First Quarter 2018 Financial Highlights

As of March 31, 2018, Hemispherx had $4.6 million in cash and cash equivalents, compared to $2.1 million at December 31, 2017. Cash used in operations was $2.5 million for the three months ended March 31, 2018, compared to $3.0 million in the same quarter in 2017. The net loss from operations was $2.7 million, or $0.07 per share, for the first quarter of 2018, compared to a net loss of $2.8 million, or $0.11 per share, for the first quarter of 2017.

A

bout Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for the treatment of serious and debilitating disorders. Hemispherx's flagship products include the FDA-approved drug Alferon N Injection® and the Argentina-approved drug rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is a double-stranded RNA being developed for globally important diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Because rintatolimod has not been designated safe and effective by the FDA for general use, it is legally available in the United States only through clinical trials. However, Ampligen® has been approved in Argentina for ME/CFS and the company is working toward legal access in other countries where early access programs exist for serious diseases with unmet medical needs, such as ME/CFS. Ampligen® is the only therapy approved anywhere in the world for ME/CFS. An Ampligen® Early Access Program (EAP) approval has also been obtained for therapeutic use in the Netherlands for pancreatic cancer.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Contact

Hemispherx Biopharma

Phone Number: 800-778-4042

Email: IR@hemispherx.net

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
16 May
 
Hej,   Jeg har været herinde i dette forum siden 2010, og har fulgt mange debatører, men en af dem s..
28
17 May
PNDORA
Jeg personligt mener at en stor del af skribenterne her på forum og markedet som helhed overreagerer..
17
16 May
PNDORA
Pandora dykkede fordi der manglede 60 millioner i omsætning ud af 1.500 millioner. Det er jo helt gr..
16
19 May
PNDORA
Pandora realiserede i Q1 2018 en omsætning, som var 44 mDKK lavere end 1Q 2017, såfremt valutakurser..
14
17 May
NOVO-B
Trump fik fortalt at PBM'ernes rabatsystem er taget for fremskaffelse af lavere priser til patienter..
14
18 May
DANSKE
Kongsmart, Jensen og Pedersen var de 3 sidste kandidater til en højt betroet post i banken. De mangl..
13
15 May
VELO
Har lyttet til det nu. Ikke så meget nyt, men bider mærke i, at Envarsus bliver mere og mere en fast..
13
14 May
VELO
Nu begynder Veloxis at levere varen. Det er klart, at med en vækst 142% i omsætning i forhold til Q1..
13
14 May
NOVO-B
Nu vil jeg ikke bruge meget tid på dit "Sikken dog noget sludder"  udover, at det er klart, at du ik..
13
19 May
PNDORA
Når nu det kan være så svært, at tolke shortere, og andre på markedet, så kan det være en god ide, a..
12

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Lambert Catches Record-Breaking Limit to Take Lead after Day Three of FLW Tour at Kentucky Lake Presented by Costa Sunglasses
2
ALGT LOSS ALERT: Rosen Law Firm Reminds Allegiant Travel Company Investors of Important Deadline in Class Action– ALGT
3
PRF: Consolidated Unaudited Interim Report of AS PRFoods for 1st quarter of 2018 and 15 months of 2017/2018
4
TheRecover.com, Drug Detoxification For San Jose Residents
5
Quick Weight-Loss Diet Plan To Lose Weight Fast With The 2 Week Diet By Brian Flatt

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 May 2018 02:13:58
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180515.2 - EUROWEB5 - 2018-05-21 03:13:58 - 2018-05-21 02:13:58 - 1000 - Website: OKAY